|
Group
|
First assessment [cases (%)]
|
Second assessment [cases (%)]
|
Third assessment [cases (%)]
|
|---|
|
FEC arm
|
151
|
132
|
68
|
|
cCR
|
0 (0.00)
|
1 (0.76)
|
3 (4.41)
|
|
cPR
|
70 (46.36)
|
76 (57.58)
|
51 (75.00)
|
|
cSD
|
67(44.37)
|
45 (34.09)
|
13 (19.12)
|
|
cPD
|
6 (3.97)
|
7 (5.30)
|
1 (1.47)
|
|
Missing
|
8 (5.30)
|
3 (2.27)
|
0 (1.47)
|
|
PE arm
|
142
|
121
|
49
|
|
cCR
|
1 (0.70)
|
6 (4.96)
|
5 (10.20)
|
|
cPR
|
97 (68.31)
|
92 (76.03)
|
41 (83.67)
|
|
cSD
|
35 (24.65)
|
20 (16.53)
|
2 (4.08)
|
|
cPD
|
3 (2.11)
|
3 (2.48)
|
1 (2.04)
|
|
Missing
|
6 (4.23)
|
0 (0.00)
|
0 (0.00)
|
-
FEC tri-weekly 5-fluorouracil–epirubicin–cyclophosphamide regimen, PE weekly paclitaxel–epirubicin regimen, cCR clinical complete response, cPR clinical partial response, cSD clinical stable disease, cPD clinical progressive disease
